Treatment variations in localised prostate cancer in Australia and New Zealand: a registry study
BJU International · 2025
DOI: 10.1111/bju.16896 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJU International, 2025. Verfasst von Karen Chiam und 13 weiteren Autor:innen. Beteiligte Einrichtung: The Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Movember Foundation.
Abstract (Originalsprache)
Objective
To describe the patterns of care and factors associated with treatment uptake of localised prostate cancer, using the bi‐national Prostate Cancer Outcomes Registry–Australia and New Zealand (PCOR‐ANZ) database.
Methods
Data for 36 504 patients, diagnosed between 2015 and 2018, from New Zealand and seven Australian jurisdictions were evaluated. Multinomial logistic regression was performed to identify factors associated with the likelihood of receiving no active treatment, radiotherapy (RT), androgen deprivation therapy (ADT) and combined ADT + RT, compared to radical prostatectomy (RP).
Results
The most common disease risk group and treatment were intermediate‐risk disease (49.2%) and RP (40.3%). Men with low‐risk disease were mostly managed by no active treatment (81.5%). Compared to men treated with RP, the likelihood of receiving other treatments was higher in residents from regional areas, those from lower socio‐economic status (SES) areas and those diagnosed at regional or public hospitals. Being in the lowest SES group was associated with an odds ratio (OR) of 1.84, (95% confidence interval [CI] 1.67–2.02) of having no active treatment, an OR of 1.53 (95% CI 1.32–1.78) for RT, an OR of 2.66 (95% CI 2.10–3.36) for ADT and an OR of 2.56 (95% CI 2.23–2.93) for ADT + RT.
Conclusions
Factors related to SES and hospital provider were associated with treatment choices in localised prostate cancer patients, independent of their age or disease risk classification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, New South Wales, Australia.
- Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia.
- Sydney School of Public Health, Faculty of Health and Medicine, The University of Sydney, Sydney, New South Wales, Australia.
- Speciality of Surgery, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
- Department of Urology, Westmead Hospital, Westmead, New South Wales, Australia.
- Department of Urology, Eastern Health, Box Hill, Victoria, Australia.
ORCID-Profile: Karen Chiam, Visalini Nair-Shalliker, Shomik Sengupta, Henry Woo, Michael O'Callaghan
Förderung
- Movember Foundation
Zitieren
APA
Chiam, K., Bang, A., Nair-Shalliker, V., Caruana, M., Patel, M. I., Sengupta, S., Vela, I., Kneebone, A., Woo, H., O'Callaghan, M., Higgs, B., Jay, A., Canfell, K., & Smith, D. P. (2025). Treatment variations in localised prostate cancer in Australia and New Zealand: a registry study. BJU International. https://doi.org/10.1111/bju.16896
Vancouver
Chiam K, Bang A, Nair-Shalliker V, Caruana M, Patel MI, Sengupta S, et al. Treatment variations in localised prostate cancer in Australia and New Zealand: a registry study. BJU International. 2025. doi:10.1111/bju.16896
BibTeX
@article{Chiam2025,
author = {Chiam, Karen and Bang, Albert and Nair-Shalliker, Visalini and Caruana, Michael and Patel, Manish I and Sengupta, Shomik and Vela, Ian and Kneebone, Andrew and Woo, Henry and O'Callaghan, Michael and Higgs, Braden and Jay, Alex and Canfell, Karen and Smith, David P},
title = {Treatment variations in localised prostate cancer in Australia and New Zealand: a registry study},
journal = {BJU International},
year = {2025},
doi = {10.1111/bju.16896}
}
EUVIMED